E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study

Vidhya Sreekumar, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, Jyotirmoyee Jena.

Abstract
Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit. The introduction of dual peroxisome proliferator-activated receptors agonist has provided a new insight into the management of both diabetes and dyslipidemia.

Aim and Objective: Hence, this study aimed to compare the effect of saroglitazar and pioglitazone on the lipid parameters and glycemic profile in patients of diabetes mellitus with dyslipidemia.

Materials and Methods: Adult patients with diabetic mellitus with dyslipidemia fulfilling the inclusion criteria were included in the study. One group received saroglitazar (4 mg/day) and the other group received pioglitazone (15 mg/day). Lipid parameters; triglyceride (TG), low-density lipoprotein, high-density lipoprotein (HDL), and serum cholesterol levels and glycemic parameters; fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycosylated hemoglobin (HbA1C) were measured at baseline and month 3, 6, and 12.

Results: Significant improvement seen in TG and HDL level at month 12 from baseline in both the treatment groups but saroglitazar was more effective than pioglitazone (P < 0.05). FPG, PPPG, and HbA1C were also reduced significantly from the baseline at the end of the study period (P < 0.05). Both the drugs were not associated with any sever adverse drug reactions.

Conclusion: The current study showed that saroglitazar was more effective than pioglitazone in controlling lipid and glycemic parameters in diabetic patients with dyslipidemia.

Key words: Diabetes Mellitus; Glycemic Parameters; Dyslipidemia


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Vidhya Sreekumar
Articles by Dayanidhi Meher
Articles by Siddhartha Goutam
Articles by Manas Ranjan Mishra
Articles by Ratikanta Tripathy
Articles by Jyotirmoyee Jena
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol. 2021; 11(5): 514-518. doi:10.5455/njppp.2021.11.01006202112012021


Web Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. http://www.njppp.com/?mno=38973 [Access: May 01, 2021]. doi:10.5455/njppp.2021.11.01006202112012021


AMA (American Medical Association) Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol. 2021; 11(5): 514-518. doi:10.5455/njppp.2021.11.01006202112012021



Vancouver/ICMJE Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol. (2021), [cited May 01, 2021]; 11(5): 514-518. doi:10.5455/njppp.2021.11.01006202112012021



Harvard Style

Sreekumar, V., Meher, . D., Goutam, . S., Mishra, . M. R., Tripathy, . R. & Jena, . J. (2021) Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol, 11 (5), 514-518. doi:10.5455/njppp.2021.11.01006202112012021



Turabian Style

Sreekumar, Vidhya, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, and Jyotirmoyee Jena. 2021. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. National Journal of Physiology, Pharmacy and Pharmacology, 11 (5), 514-518. doi:10.5455/njppp.2021.11.01006202112012021



Chicago Style

Sreekumar, Vidhya, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, and Jyotirmoyee Jena. "Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 514-518. doi:10.5455/njppp.2021.11.01006202112012021



MLA (The Modern Language Association) Style

Sreekumar, Vidhya, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, and Jyotirmoyee Jena. "Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study." National Journal of Physiology, Pharmacy and Pharmacology 11.5 (2021), 514-518. Print. doi:10.5455/njppp.2021.11.01006202112012021



APA (American Psychological Association) Style

Sreekumar, V., Meher, . D., Goutam, . S., Mishra, . M. R., Tripathy, . R. & Jena, . J. (2021) Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. National Journal of Physiology, Pharmacy and Pharmacology, 11 (5), 514-518. doi:10.5455/njppp.2021.11.01006202112012021